Silexion Therapeutics Submits Phase 2/3 CTA for Pancreatic Cancer Drug in Germany
Summary
Silexion Therapeutics officially filed an 8-K announcing the successful submission of its Phase 2/3 Clinical Trial Application for SIL204 in pancreatic cancer to German regulators, a key step for its European clinical program.
Key Events
-
Phase 2/3 CTA Submitted in Germany
Silexion Therapeutics successfully submitted a Clinical Trial Application (CTA) to Germany's BfArM for its lead candidate, SIL204, for KRAS-driven locally advanced pancreatic cancer.
-
European Clinical Expansion
Germany will serve as the Reporting Member State for the planned EU Phase 2/3 clinical program, marking a significant expansion into the European regulatory process.
-
Follows Israeli Approval
This submission builds on positive Scientific Advice from BfArM in December 2025 and recent approval from the Israeli Ministry of Health for the same Phase 2/3 trial.
-
Addresses Critical Unmet Need
SIL204 targets KRAS-driven pancreatic cancer, a highly lethal malignancy with significant unmet medical needs, using an innovative dual-route administration strategy.
Analysis
This 8-K announces a critical regulatory milestone for Silexion Therapeutics, a clinical-stage biotech facing a "going concern" warning. The successful submission of a Phase 2/3 Clinical Trial Application (CTA) to Germany's BfArM for its lead candidate, SIL204, in KRAS-driven pancreatic cancer, expands its clinical development into a major European market. This follows recent approval in Israel and is vital for the company's pipeline progression and future financing efforts, offering a positive signal amidst financial challenges.
At the time of this filing, SLXN was trading at $0.76 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3M. The 52-week trading range was $0.70 to $22.36. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.